Q1 sales +40% y-o-y, +2% q-o-q, FCF negative Cut '25e-'27e sales by 7% on weaker Q2 outlook Market r...
STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products app...
Angler Gaming plc (”Angler” eller ”Bolaget”) levererade en kv1 2025-rapport under vår förväntan avse...
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 16 maj 2025 att Bolaget mottagit en ny orde...
Soft Q1 earnings driven by gross margin pressure in the US Weaker USD weighs on estimates, given US-...
Redeye provides an update following CLS’s Q1 2025 report.
Redeye states Safello's report came in on the weaker side in a quarter with a challenging backdrop.
Redeye provides an update following Paxman’s Q1 2025 report.
Portfolio rebalancing and weak market behind PW We lower '25e-'27e EBIT by 31-22% on lower sales We ...
Q1 miss, 2025-27e adj. EBITA cut 4-5% FY guidance kept, we estimate 7% EBITA growth in 2025e Share a...
Sales SEK 54m (ABGSCe 55m), EBIT -4m (ABGSCe -7m) Market conditions remain soft, anticipates weaker ...
Redeye provides a brief summary of Elicera’s Q1'25 report.
Voi, som är VNV Globals näst största innehav, kom med en stark Q1-rapport.
Omsättningen sjönk till 8,2 (10,2) meur, varav PremierGaming stod för 6,7%.
The FDA submission is progressing toward the finish line, as illustrated by the more precise expecte...
Cantargia har investerat i en stor fas -1 studie med CAN10 för att skaffa ett bra underlag inför näs...
1% organic growth (cons 4%) and EBITA -13% vs cons Reiterates 2025 guidance of EBITA 2024, Q1 EBITA ...
Orviglance FDA submission during the summer Good cost control Conf call at 10:00 CEST Recent releva...
Redeye provides an update on Thunderful Group following its Q1 2025 report, which was better than ex...
Redeye updates its estimates after reviewing Fable Media Group’s Q1 report, which was softer than ou...
